CHERUB Scientific Leadership
The CHERUB Collaboration is led by a Scientific Steering Committee (SSC) with representatives from key partners including the community of people living with HIV.
The day-to-day management of the CHERUB Collaboration is led by the CHERUB leadership team with support from the dedicated CHERUB Project Manager at Imperial College London.
Sarah Fidler - Imperial College London
Professor of HIV and Communicable Diseases; Consultant Physician
Sarah has been involved in designing and leading HIV international clinical studies for participants identified in acute HIV infection, and small proof of concept studies in HIV cure.
John Frater - Oxford University
Scientific lead and co-chair of CHERUB
John has been involved in research focusing on quantification of viral reservoirs, sequence analysis by standard and next generation models, immunology (predominantly looking at the role of CTL in remission strategies) and more fundamental research into new approaches to eradication such as nanotechnology. Working in collaboration with NHS Trusts and with the pharmaceutical industry, the aim to push forward the boundaries in this new and exciting field.
Julie Fox - King's College London
HIV Consultant
HIV consultant that runs the HIV clinical trials unit and carries out studies in HIV prevention and HIV therapeutics. A part of the UK CHERUB collaboration investigating approaches to finding a cure for HIV and leads an HIV prevention programme in sub-Saharan Africa.
Ravindra Gupta - Cambridge University
Professor of Clinical Microbiology
Research in the Gupta lab focuses on host-pathogen and drug-pathogen interactions to inform HIV treatment and curative strategies. His programme of work is informed by clinical work as an infectious diseases physician in London where he has been able to study unique individuals with HIV in order to better understand viral reservoirs and immune control of HIV. Excitingly, he is currently conducting a study in collaboration with Imperial College aiming to demonstrate the world’s second HIV cure by stem cell transplantation.
Lucy Dorrell - Immunocore / Oxford University
Head of Disease Biology, Infectious Diseases, Immunocore; Professor of Immunology, Oxford University
Group leader for studies surrounding two major groups of viruses ; lentiviruses (retroviruses) and rotaviruses. The lentiviruses include HIV-1, HIV-2 and FIV. In all of these viruses, the focus is on virus assembly, how the virus captures its RNA genome within the cell and how it uses cellular machinery to do this
John Thornhill - Barts Health NHS Trust
Consultant Physician in Sexual Health and HIV
Senior Clinical Research Fellow with an interest in the role of HIV tissue reservoirs and immune dysfunction in HIV persistence. Involved in clinical HIV cure intervention studies at the HIV clinical trials centre at St. Marys Hospital
Clinical Scientist
Clinical Scientist in Antiretroviral therapy in early HIV-1 infection, HIV-1 functional cure and eradication, Prophylactic HIV-1 vaccine.
Andrew Lever - Cambridge University
Professor of Infectious Diseases
Studying surrounding two major groups of viruses ; lentiviruses (retroviruses) and rotaviruses. The lentiviruses include HIV-1, HIV-2 and FIV. In all of these viruses, the focus is on virus assembly, how the virus captures its RNA genome within the cell and how it uses cellular machinery to do this.
